Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,159,027 shares of Ionis Pharmaceuticals common stock, representing 3.7% of the class. The filing states sole voting power over 6,140,820 shares and sole dispositive power over 6,159,027 shares.
The filing is an amendment (Schedule 13G/A, Amendment No. 5) signed on 05/15/2026 and includes a statement that the filer denies beneficial ownership for the securities referenced. The CUSIP is 462222100 and the issuer is Ionis Pharmaceuticals, Inc.
Capital World Investors filed an amended Schedule 13G/A reporting beneficial ownership of 21,186,369 shares of Ionis Pharmaceuticals common stock, representing 12.8% of the 165,192,011 shares outstanding as of 03/31/2026. The filing states CWI has sole voting and dispositive power over these shares. The amendment is signed by a CRMC officer on 05/13/2026.
IONS — Form 144 notice of proposed sale by an affiliate. The filing lists proposed sales of Common Stock by Brett Monia, including 126,670 shares on 03/09/2026 for $9,525,059.00 and 34,103 shares on 03/10/2026 for $2,589,144.00. The filing also lists two historic stock option grants of 50,000 shares each (01/04/2021 and 01/03/2022) described as Equity Compensation.
Ionis Pharmaceuticals director Joseph Loscalzo reported paired option exercises and stock sales on May 4, 2026. He sold a total of 77,289 shares of Common Stock in open-market transactions at weighted average prices of $75.58 and $74.90, under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 18, 2025. To fund these sales, he exercised non-qualified stock options covering 77,289 shares at exercise prices between $38.06 and $64.80. Following the transactions, he continued to hold more than 36,000 shares of Ionis stock directly.
Ionis Pharmaceuticals director Joseph Klein III exercised a non-qualified stock option for 10,111 shares of common stock at an exercise price of $47.11 per share and, on the same date, sold 10,111 shares in open-market transactions under a pre-arranged Rule 10b5-1 Trading Plan. The sales consisted of 8,680 shares at a weighted-average price of $73.3530 and 1,431 shares at a weighted-average price of $74.4474. Following these transactions, Klein held 11,014 shares of Ionis common stock directly. An additional 100 shares are held indirectly by his son, and Klein disclaims beneficial ownership of those shares.
Form 144 notice of proposed sales of Common Stock tied to option exercises and recent open‑market dispositions. The filing lists multiple option‑exercise issuances dated 07/01/2021, 07/03/2023, 07/02/2018, 07/01/2020, and 07/01/2019 for 12,000; 10,321; 16,000; 12,000; and 16,000 shares respectively. It also reports that Joseph Loscalzo sold 832 shares on 03/03/2026 for $66,833 and 200 shares on 03/04/2026 for $16,000.
Ionis Pharmaceuticals executive Joseph Baroldi reported an open-market sale of company stock. On this Form 4, the EVP and Chief Business Officer sold 1,626 shares of Ionis Pharmaceuticals common stock on April 28, 2026 at a weighted average price of $71.7877 per share in an open-market transaction.
The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by Baroldi on November 25, 2025. After the transaction, he directly owned 44,909 shares of common stock. A separate holding entry shows 4,347 shares of common stock held indirectly by his spouse.
Vanguard Capital Management reported beneficial ownership of 8,344,732 shares of Ionis Pharmaceuticals common stock, representing 5.05% of the class. The filing lists sole voting power over 1,226,402 shares and sole dispositive power over 8,344,732 shares. The Schedule 13G is signed by Vanguard's Head of Global Fund Administration.
Ionis Pharmaceuticals reported strong growth for the quarter ended March 31, 2026, with total revenue of $246.1 million, up from $131.6 million a year earlier, driven by new product launches and collaboration milestones. Product sales rose to $43.0 million, led by TRYNGOLZA and DAWNZERA, while royalty revenue was $58.3 million. Research and development revenue more than doubled to $138.3 million, helped by a $50 million milestone from Roche and $30 million of milestones from GSK. The company’s net loss narrowed to $92.5 million, compared with $146.9 million in the prior-year quarter, as higher revenue offset increased commercial and R&D spending. Ionis ended the quarter with $173.4 million in cash and cash equivalents and $1.75 billion in short-term investments, supporting ongoing launches and late-stage development, despite a large operating cash outflow related to funding the upcoming maturity of its 0% convertible notes due 2026.
Ionis Pharmaceuticals reported strong first quarter 2026 results and raised its full-year outlook. Total revenue rose to $246 million from $132 million a year earlier, driven by higher product sales of TRYNGOLZA and DAWNZERA and increased research and development revenue, including about $95 million of partnership milestones.
Despite the growth, Ionis recorded a GAAP net loss of $93 million, improving from a $147 million loss last year. Cash, cash equivalents and short-term investments were $1.9 billion as of March 31, 2026, with an additional $633 million held in escrow for 0% convertible notes maturing in April 2026.
Reflecting its momentum, Ionis increased 2026 total revenue guidance to $875–900 million and introduced product sales targets of $100–110 million for TRYNGOLZA and $110–120 million for DAWNZERA. The company also narrowed its expected 2026 non-GAAP operating loss to $425–475 million and reaffirmed a year-end liquidity goal of more than $1.6 billion.